<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391688</url>
  </required_header>
  <id_info>
    <org_study_id>14-061</org_study_id>
    <nct_id>NCT02391688</nct_id>
  </id_info>
  <brief_title>Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Desmeules</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phenotyping is an approach largely used for the evaluation of the activity of cytochromes and
      transporters in vivo. It consists of the administration of probe substances metabolised by a
      specific cytochrome or transported by P-glycoprotein (P-gp) for example, followed by the
      determination of a metabolic ratio or the evaluation of the plasmatic or urinary
      concentrations of the probe substances. The administration of a cocktail containing several
      probe substances allows the simultaneous evaluation of the activity of several cytochromes
      and P-gp in a single test.

      When a cocktail approach is used it is important to make sure that no drug-drug interactions
      occur between the probes within the cocktail. The validation of the lack of interactions,
      which is the aim of the study, consists of demonstrating that there is no difference in the
      pharmacokinetic parameters and/or metabolic ratios when a probe is administered alone or as
      part of the cocktail. The Geneva cocktail consists of caffeine, bupropion, flurbiprofen,
      omeprazole, dextromethorphan, midazolam and fexofenadine for the simultaneous phenotyping of
      CYP1A2, CYP2B6, CYP2C9, CAP2C19, CYP2D6, CYP3A4 and P-gp, respectively.

      Probe and metabolite concentrations will be measured in capillary blood using a dried blood
      spot (DBS) analysis. To further facilitate sampling, a new simple device will be used to
      ensure the precision of capillary blood collection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the capillary blood concentration-time curve (AUC) of caffeine</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D</time_frame>
    <description>Comparison of caffeine AUC when treatment A or D is administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the capillary blood concentration-time curve (AUC) of dextromethorphan</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D</time_frame>
    <description>Comparison of dextromethorphan AUC when treatment A or D is administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the capillary blood concentration-time curve (AUC) of flurbiprofen</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D</time_frame>
    <description>Comparison of flurbiprofen AUC when treatment A or D is administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the capillary blood concentration-time curve (AUC) of midazolam</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D</time_frame>
    <description>Comparison of midazolam AUC when treatment A or D is administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the capillary blood concentration-time curve (AUC) of omeprazole</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D</time_frame>
    <description>Comparison of omeprazole AUC when treatment A or D is administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the capillary blood concentration-time curve (AUC) of fexofenadine</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment B or D</time_frame>
    <description>Comparison of fexofenadine AUC when treatment B or D is administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the capillary blood concentration-time curve (AUC) of bupropion</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post treatment C or D</time_frame>
    <description>Comparison of bupropion AUC when treatment C or D is administered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio (MR) of paraxanthine blood concentration /caffeine blood concentration</measure>
    <time_frame>0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D</time_frame>
    <description>Comparison of paraxanthine/caffeine MRs between treatment A and D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio (MR) of dextrorphan blood concentration /dextromethorphan blood concentration</measure>
    <time_frame>0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D</time_frame>
    <description>Comparison of dextrorphan/dextromethorphan MRs between treatment A and D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio (MR) of 4-hydroxyflurbiprofen blood concentration /flurbiprofen blood concentration</measure>
    <time_frame>0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D</time_frame>
    <description>Comparison of 4-hydroxyflurbiprofen/flurbiprofen MRs between treatment A and D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio (MR) of 1-hydroxymidazolam blood concentration /midazolam blood concentration</measure>
    <time_frame>0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D</time_frame>
    <description>Comparison of 1-hydroxymidazolam/midazolam MRs between treatment A and D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio (MR) of 5-hydroxyomeprazole blood concentration /omeprazole blood concentration</measure>
    <time_frame>0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D</time_frame>
    <description>Comparison of 5-hydroxyomeprazole/omeprazole MRs between treatment A and D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio (MR) of 4-hydroxybupropion blood concentration /bupropion blood concentration</measure>
    <time_frame>0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post treatment C or D</time_frame>
    <description>Comparison of 4-hydroxybupropion/bupropion MRs between treatment C and D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>at each drug administration day</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of drug concentrations (ng/ml) in DBS obtained with two sampling techniques for all administered drugs</measure>
    <time_frame>0.5, 1, 2, 3, 4, 6, 8 hours post treatment A, B, C and D</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Drug Interaction</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral intake of:
caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral intake of:
fexofenadine 25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral intake of:
bupropion 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Intake of Geneva cocktail (A+B+C):
caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg fexofenadine 25 mg bupropion 20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers aged from 18 to 60 years

          -  BMI between 18 and 27

          -  Understanding of French language and able to give a written inform consent.

        Exclusion Criteria:

          -  smoker

          -  pregnant women

          -  taking drugs which alter cytochrome P450 (CYP) activity

          -  renal or hepatic impairment

          -  medical history of chronic alcoholism or abuse of psychoactive drugs

          -  liver transplantation

          -  sensitivity to any of the drugs used

          -  Alteration of hepatic tests, more than 2x normal (aspartate transaminase &gt;100U/L ;
             alanine transaminase &gt;100 units/L ; gamma-glutamyl transferase &gt;80 units/L ; bilirubin
             &gt;50µmol/L)

          -  Presenting genetic polymorphism of poor CYP2C9, CYP2C19, CYP2D6 metabolizer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre de Recherche Clinique, HUG, Rue Gabrielle Perret-Gentil 4</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Jules Desmeules</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

